Daniel G. Welch

Daniel G. Welch

Biotechnology Executive (Executive Chairman)

Dan has spent his career of forty years in the business of developing medicines.

From January 2015 to February 2018, Dan was an Executive Partner of Sofinnova, a bay area biotech venture capital firm. Prior to joining Sofinnova, he was Chairman and CEO of InterMune until its acquisition by Roche in October of 2014. Before InterMune, Dan was Chairman and CEO of Triangle Pharmaceuticals, which was acquired by Gilead in 2003. Prior to Triangle, Dan was President of Biopharmaceuticals at Elan Corporation where he was responsible for its worldwide pharmaceutical operations, R&D and the diagnostics businesses. From 1987 to 2000, he served in various senior management roles at Sanofi, including General Manager, Vice President of Worldwide Marketing and Chief Operating Officer of the U.S. business.

Mr. Welch’s past board service includes a directorship at Hyperion Therapeutics until it was acquired by Horizon Pharma in 2015 and Chairman of the Board of AveXis Inc. until it was acquired by Novartis Pharmaceuticals in 2018.

Mr. Welch currently serves on several boards: Chairman of the Board of Ultragenyx Pharmaceuticals; Executive Chairman of Levo Therapeutics; Executive Chairman of InCarda; director of Seattle Genetics and Intercept Pharmaceuticals.

Mr. Welch holds a B.A. degree from the University of Miami and an M.B.A. degree from the University of North Carolina

For more information about InCarda: